Abstract: Objective 　To compare the clinical efficacy and application between t ransarterial infusion chemotherapy and systemic venous chemotherapy in t reating patient s with advanced pancreatic carcinoma. Methods 　Of 51 advanced pancreatic carcinoma patient s, 25 received gemcitabine combined with 5-fluorouracil via transarterial continuous infusion chemotherapy ( group A) . 26 cases received gemcitabine combined with 5-fluorouracil via systemic venous chemotherapy (group B) . Tumor response rate, clinical benefit response (CBR) and toxicity were observed. All of the date was analyzed with SPSS 13. 0 statistics sof tware. Results 　The tumor response rate was 32. 0 % in group A, and 23. 1 % in group B, but there was no significant difference in the tumor response rate ( P = 0. 475, Chi-square test) . The clinical benefit response (CBR) were 80. 0 % and 50. 0 % respectively, and there was a significant difference in CBR between two groups ( P = 0. 025, Chi2square test) . There was a significant difference between two groups ( P = 0. 002, Chi2square test) of the 62 month, 92month, 12 year survival rates and median survivals. According to WHO criterion, There was no significant difference in the incidence of hematological and nonhematological toxicity between two groups. Conclusion 　The combination gemcitabine and 5-fluorouracil via continuous transarterial infusion chemotherapy in treating patient s with advanced pancreatic carcinoma is a moderatedly active t reatment . It has definite response rate and also significantly improve the quality of life in patients. Its treatment value is worth further studing.